Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 LA BioMed Opens Medical Research Building | Contract Pharma
Breaking News

LA BioMed Opens Medical Research Building

$63-million, four-story, 78,000 square-foot facility is one of the most advanced in the country

The Los Angeles Biomedical Research Institute (LA BioMed) held the grand opening of its new state-of-the-art medical research building and bioscience incubator on its campus at Harbor-UCLA Medical Center in Torrance.
 
“The opening of our new medical research building is a milestone for LA BioMed,” said David Meyer, president and chief executive officer, LA BioMed. “It will allow us to recruit and retain the best investigators, giving them world-class labs and work spaces where they can develop new treatments and therapeutics for years to come.”
 
The $63-million, four-story, 78,000 square-foot facility is one of the most advanced medical research buildings in the country. It contains both wet and dry labs, freezer farms, an auditorium that can seat over 150 people, and an 18,000 square-foot bioscience incubator operated by BioLabs, called BioLabs LA BioMed, that can host up to 30 bioscience startups and offers $1 million in shared equipment, private offices and meeting space.
 
“LA BioMed’s new research facility, with its state-of-the art bioscience incubator, holds the promise of medical advances and discoveries that can transform the way we diagnose and treat diseases, potentially saving lives,” said supervisor Mark Ridley-Thomas. “And it is only one of many initiatives currently under way to make Los Angeles County a world leader in bioscience.”
 
LA BioMed has a track record of commercializing discoveries, having spun off 13 startups in the last 12 years. Those include Emmaus Medical, which has developed a treatment for sickle cell disease that is approved by FDA, and NovaDigm Therapeutics, which is developing vaccines for fungal and bacterial infections commonly contracted at hospitals. The institute has also licensed products to two publicly-traded companies, including Kybella, a popular injectable treatment that removes fat from under the chin.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters